The upcoming trials of an inexpensive drug that is already used to lower high cholesterol levels will be watched closely by doctors as well as patients who suffer from Multiple Sclerosis (MS).
In 2014, trials found that MS patients who were administered Simvastatin showed significant reductions in brain atrophy levels, compared to those who were not given the drug. That was a smaller trial with just 140 participants, but a new larger trial that is due to begin soon will focus on more than 1,100 people, and will try to confirm the results of the earlier study.
The new study will specifically look at whether the administration of Simvastatin helps reduce the progression of MS in patients. Researchers are optimistic that the drug holds plenty of potential for millions of Multiple Sclerosis sufferers in the United Kingdom – where the trial will be conducted – and around the world.